Table 3.
Different neutralizing antibodies which are in the pre-clinical trial.
| Sl. No. | nAb | International Nonpropreitary Name (INN) | Source | Type |
|---|---|---|---|---|
| 1. | LY-CoV555 | Bamlanivimab | Human B cells | mAb human IgG1 |
| 2. | JS016 | Etesevimab + Bamlanivimab | Human B cells | mAb human, combination of 2 mAb |
| 3. | LY-CoV016 | Etesevimab + Bamlanivimab | Human B cells | mAb human, combination of 2 mAb |
| 4. | LY3832479 | Etesevimab + Bamlanivimab | Human B cells | mAb human, combination of 2 mAb |
| 5. | REGN-COV2 | Casirivimab + Imdevimab | Convalescent sources and immunization | mAb human |
| 6. | TY027 | - | - | mAb |
| 7. | BRII-196 | - | Human B cells | mAb human |
| 8. | BRII-198 | - | Human B cells | mAb human |
| 9. | CT-P59 | Regdanvimab | Human B cells | mAb human |
| 10. | SCTA01 | - | - | mAb humanized |
| 11. | SAB- 185 |
- | Immunization | Polyclonal recombinant human Ab |
| 12. | MW33 | - | - | mAb human |
| 13. | AZD7442 | Tixagevimab + Cilgavimab | Human B cells | mAb human |
| 14. | VIR-7831 | Sotrovimab | Human B cells | mAb human |
| 15. | DXP-593 | - | Human B cells | mAb |
| 16. | Anti-SARS-CoV-2 mAb | - | - | mAb, chicken IgY |
| 17. | ABBV-47D11 | - | Immunization | mAb human IgG1 |
| 18. | DXP604 | - | Human B cells | mAb |
| 19. | COVI-AMG (STI-2020) | - | In vitro libraries | mAb human |
| 20. | C144-LS and C-135-LS | - | - | Mixture of 2 mAb |
| 21. | ADG20 | - | Human B cells | mAb human |
| 22. | COR-101 | - | In vitro libraries and human B cells | mAb human |